The most recent consensus statement on acromegaly therapeutic outcomes (15) discretionarily recommends that clinician-reported outcome instruments such as SAGIT (Signs and symptoms, Associated comorbidities, GH levels, IGF1 levels, and Tumor profile) (13) and ACRODAT (Acromegaly Disease Activity Tool) (14) could be potentially used to assess and monitor indicators of disease activity. This evidence concerns the gene IGF1 and acromegaly.